Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
advisory committee
Biotech
FDA delays decision on Biohaven troriluzole filing, plans adcomm
Forty-eight hours after saying its filing was on track, the biopharma revealed the FDA has delayed a decision on its rare disease drug troriluzole.
Nick Paul Taylor
May 15, 2025 6:02am
Lilly's donanemab sails through FDA meeting with 2 yes votes
Jun 10, 2024 5:11pm
Lykos' MDMA treatment rejected by FDA committee
Jun 5, 2024 10:20am
Guardant preps for FDA review of colorectal cancer blood test
May 13, 2024 1:48pm
FDA wants to hear from you on future of adcomm meetings
Apr 29, 2024 12:51pm
FDA's Richard Pazdur explains confirmatory trial rejection, more
Apr 8, 2024 6:00am
